Apoptosis

, Volume 22, Issue 6, pp 769–776 | Cite as

Relaxin attenuates aristolochic acid induced human tubular epithelial cell apoptosis in vitro by activation of the PI3K/Akt signaling pathway

  • Xiang-Cheng Xie
  • Ning Zhao
  • Qun-Hong Xu
  • Xiu Yang
  • Wen-Kai Xia
  • Qi Chen
  • Ming Wang
  • Xiao Fei
Article

Abstract

Aristolochic acid nephropathy remains a leading cause of chronic kidney disease (CKD), however few treatment strategies exist. Emerging evidence has shown that H2 relaxin (RLX) possesses powerful antifibrosis and anti-apoptotic properties, therefore we aimed to investigate whether H2 relaxin can be employed to reduce AA-induced cell apoptosis. Human proximal tubular epithelial (HK-2) cells exposed to AA-I were treated with or without administration of H2 RLX. Cell viability was examined using the WST-8 assay. Apoptotic morphologic alterations were observed using the Hoechst 33342 staining method. Apoptosis was detected using flow cytometry. The expression of caspase 3, caspase 8, caspase 9, ERK1/2, Bax, Bcl-2, and Akt proteins was determined by Western blot. Co-treatment with RLX reversed the increased apoptosis observed in the AA-I only treated group. RLX restored expression of phosphorylated Akt which found to be decreased in the AA-I only treated cells. RLX co-treatment led to a decrease in the Bax/Bcl-2 ratio as well as the cleaved form of caspase-3 compared to the AA-I only treated cells. This anti-apoptotic effect of RLX was attenuated by co-administration of the Akt inhibitor LY294002. The present study demonstrated H2 RLX can decrease AA-I induced apoptosis through activation of the PI3K/Akt signaling pathway.

Keywords

Aristolochic acid nephropathy Apoptosis Human relaxin Kidney fibrosis 

Notes

Acknowledgements

This study is supported by Grants from the Hangzhou Science and Technology Committee (20150733Q06).

Authors contributions

X.C.C and F.X. designed the research protocols and drafted the paper. Z.N., Y.X., and X.Q.H conducted research. C.Q., W.K.X. and M.W. analyzed data and performed statistical analysis. All authors reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

References

  1. 1.
    Yang L et al. (2012) Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant 27:292–298CrossRefPubMedGoogle Scholar
  2. 2.
    Anandagoda N et al. (2015) Preventing aristolochic acid nephropathy. Clin J Am Soc Nephrol 10:167–168CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Debelle FD et al. (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158–169CrossRefPubMedGoogle Scholar
  4. 4.
    Vanherweghem LJ et al. (1998) Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 4:9–13CrossRefPubMedGoogle Scholar
  5. 5.
    Baudoux TE et al. (2012) Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int 82:1105–1113CrossRefPubMedGoogle Scholar
  6. 6.
    Sun D et al. (2006) Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am J Nephrol 26:363–371CrossRefPubMedGoogle Scholar
  7. 7.
    Pozdzik AA et al. (2008) Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 73:595–607CrossRefPubMedGoogle Scholar
  8. 8.
    Yang L et al. (2007) Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 22:445–456CrossRefPubMedGoogle Scholar
  9. 9.
    Debelle FD et al. (2002) Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13:431–436PubMedGoogle Scholar
  10. 10.
    Gao R et al. (2000) Aristolochic acid I-induced apoptosis in LLC-PK1 cells and amelioration of the apoptotic damage by calcium antagonist. Chin Med J (Engl) 113:418–424Google Scholar
  11. 11.
    Romanov V et al. (2011) Glutamate dehydrogenase requirement for apoptosis induced by aristolochic acid in renal tubular epithelial cells. Apoptosis 16:1217–1228CrossRefPubMedGoogle Scholar
  12. 12.
    Bunel V et al. (2015) In vitro effects of Panax ginseng in aristolochic acid-mediated renal tubulotoxicity: apoptosis versus regeneration. Planta Med 81:363–372CrossRefPubMedGoogle Scholar
  13. 13.
    Dickman KG et al. (2011) Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther 338:588–597CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhou L et al. (2010) Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 21:31–41CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Luciano RL et al. (2015) Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. Drug Saf 38:55–64CrossRefPubMedGoogle Scholar
  16. 16.
    Gu HP et al. (2012) Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology 153:3692–3700CrossRefPubMedGoogle Scholar
  17. 17.
    Cernaro V et al. (2014) Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. Med Res Rev 34:77–105CrossRefPubMedGoogle Scholar
  18. 18.
    Yoshida T et al. (2013) Relaxin protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 305:F1169–F1176CrossRefPubMedGoogle Scholar
  19. 19.
    Moore XL et al. (2007) Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148:1582–1589CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson A et al. (2013) Apoptosis and angiogenesis: an evolving mechanism for fibrosis. FASEB J 27:3893–3901CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liu MC et al. (2003) The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids. Clin Exp Nephrol 7:186–194CrossRefPubMedGoogle Scholar
  22. 22.
    Li J et al. (2010) Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol In Vitro 24:1092–1097CrossRefPubMedGoogle Scholar
  23. 23.
    Raisova M et al. (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333–340CrossRefPubMedGoogle Scholar
  24. 24.
    Hsu SY et al. (2000) Tissue-specific Bcl-2 protein partners in apoptosis: an ovarian paradigm. Physiol Rev 80:593–614PubMedGoogle Scholar
  25. 25.
    Linkermann A et al. (2014) Regulated cell death in AKI. J Am Soc Nephrol 25:2689–2701CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lu Z, Xu S (2006) ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58:621–631CrossRefPubMedGoogle Scholar
  27. 27.
    Chow BS et al. (2014) Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int 86:75–85CrossRefPubMedGoogle Scholar
  28. 28.
    McGuane JT et al. (2011) Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152:2786–2796CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yoshida T et al. (2014) Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats. Nephron Exp Nephrol 128:9–20CrossRefPubMedGoogle Scholar
  30. 30.
    McCullough PA et al. (2015) Novel markers and therapies for patients with acute heart failure and renal dysfunction. Am J Med 128:311–312CrossRefGoogle Scholar
  31. 31.
    Kuwana H et al. (2008) The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int 73:430–445CrossRefPubMedGoogle Scholar
  32. 32.
    Manning BD et al. (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Koyasu S et al. (2003) The role of PI3K in immune cells. Nat Immunol 4:313–319CrossRefPubMedGoogle Scholar
  34. 34.
    Lan A et al. (2015) Potential role of Akt signaling in chronic kidney disease. Nephrol Dial Transplant 30:385–394CrossRefPubMedGoogle Scholar
  35. 35.
    Zhou Y et al. (2009) PI3K/AKT mediated p53 down-regulation participates in CpG DNA inhibition of spontaneous B cell apoptosis. Cell Mol Immunol 6:175–180CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Xie L et al. (2006) Role of PI3-kinase/Akt signalling pathway in renal function and cell proliferation after renal ischaemia/reperfusion injury in mice. Nephrology (Carlton) 11:207–212CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Xiang-Cheng Xie
    • 1
  • Ning Zhao
    • 1
  • Qun-Hong Xu
    • 1
  • Xiu Yang
    • 1
  • Wen-Kai Xia
    • 2
  • Qi Chen
    • 1
  • Ming Wang
    • 1
  • Xiao Fei
    • 1
  1. 1.Department of Nephrology, Hangzhou First People’s HospitalNanjing Medical UniversityHangzhouChina
  2. 2.Department of NephrologyJiangyin People’s HospitalJiangyinChina

Personalised recommendations